As such, our data supports the notion that co-targeting the integrin-dependent pathway and BRD4-associated epigenetic network is an alternative therapy against NSCLC malignancy, particularly for patients carrying KRAS mutations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.